... (BCG) could reduce toxicity without compromising efficacy. From February 1991 to June 1992, 500 patients with superficial bladder cancer(TaG2-3, T1G1-3) entered the trial. Of these patients, 252 were included in group A (BCG, 81 mg) and 248 in group B (BCG, 27 mg). There were no significant differences...

...D.L. Lamm The management of superficial bladder cancer has advanced significantly in recent years. Controlled clinical trials suggest the benefits of cytotoxic chemotherapy apply primarily to well-differentiated tumours, are short-term and do not include a reduction in disease progression...

... of superficial bladder cancer. 11 8 2017 Epirubicin Mitomycin C Chemoprophylaxis Superficial bladder cancer Clinical Paper EurUrol 1992;21:42-44 Fernando Calais da Silva Fernando Ferrito Teixeira Brandäo Almeida Santos Department of Urology, Desterro Hospital, Lisbon, Portugal 4...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Intravesical chemotherapy Doxorubicin Mitomycin Mild...

...K. Höbarth; U. Maier; M. Marberger The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated. Based on our result of a previous study that this approach results in a significantly reduced recurrence...

..., Spain 1606295 Key Words. Bladder cancer Superficial bladder cancer Prostatic urethra recurrence Abstract. A comparative retrospective study was performed on 100 patients who had undergone transurethral resection of a superficial bladder tumor (Ta-Ti) with no associated carcinoma in situ (group 1...

...A. Steg; S. Adjiman; B. Debré Bacillus Calmette-Guérin (BCG) immunotherapy represents a valuable treatment in the management of superficial bladder cancer, but the therapy is not without its risks. A total of 220 patients have been included in a review of local and systemic side effects associated...

...D.L. Lamm Immunotherapy provides an effective alternative approach to chemotherapy in the management of superficial bladder cancer. The first widely used immunotherapy, bacillus Calmette-Guérin (BCG), eradicates residual tumour in one half of patients with carcinoma in situ. Unlike chemotherapy...

... with better results. BCG Superficial bladder cancer 1992 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying...

...F. Pagano; P. Bassi; C. Milani; N. Piazza; A. Meneghini; A. Garbeglio Shortly after Morales’ original report, several phase II trials confirmed the effectiveness of intravesical bacillus Calmette-Guérin (BCG) in superficial bladder cancer therapy. Concerns have been expressed about the toxicity...

...C.D. Vera-Donoso; B. Llopis; F. Oliver; J. Gallego; J. Ruiz; J. Vidal; J.F. Jiménez Cruz One hundred and five patients with superficial bladder cancer (60 primary and 45 recurrent tumors)entered a prospective chemoprophylaxis trial after transurethral resection of the tumor. The drug...

...B. Llopis; C.D. Vera-Donoso; J. Gallego; F. Boronat; J.F. Jiménez-Cruz 26 patients with superficial bladder cancer underwent complete removal of tumors by transurethral resection and entered a prospective trial of immunoprophylaxis with Calmette-Guérin bacillus (BCG). The entire group had recurrent...

..., instructions or products referred to in the content or advertisements. Superficial bladder cancer BCG immunotherapy Nonspecific immunotherapy Eur. Urol. 10: 93-100 (1984) © 1984 S. Karger AG, Basel 0302-2838/84/0102-009352.75/0 BCG Vaccine in Superficial Bladder Tumours: Eight Years Later J.A...

... such as shape change, adherence, exocytosis and respiratory burst, events that are of importance in inflammation. To study the release of NAP-1/IL-8, two human models of inflammation were chosen: transurethral resection of superficial bladder cancer and the subsequent instillation of bacillus Calmette-Guérin...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Prediction Progression Superficial bladder cancer Clinical Papers Eur. Urol. 11: 1-5(1985) © 1985 S. Karger AG...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Recurrence Invasive growth Prophylactic therapy Eur. Urol. 14: 367-370 (1988) © 1988 S Karger AG, Basel 0302 2838/88/0145 0367$2.75/0 Effects...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Immunotherapy Interferon Clinical Paper Eur Urol 1995;28:291-296 1605300 Fernando Calais da Silva Linhares Furtado Mdrio Reis Fernando Carreira Vitor Dias Gomes Oliveira...

... patients receiving BLP and in 3 of the placebo-treated patients. Oral administration of BLP was thus safe and effective for preventing recurrence of superficial bladder cancer. 11 8 2017 1995 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Pyridoxine Superficial bladder cancer Tryptophan metabolites Clinical Paper...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Risk factors Adjuvant topical therapy Survival rate Eur Urol 1990;17:113-118 1608015 © 1990 S. Karger AG, Basel...